Metabolic Program

CombinatoRx has one product candidate, CRx-401, a novel oral synergistic combination drug that has advanced into a phase 2 clinical trial for Type 2 diabetes.

Type 2 diabetic patients often have a characteristic lipid profile involving elevated triglycerides, low HDL levels and small particle size LDL with relatively normal overall LDL levels. Returning patients' blood glucose levels to near normal levels is the recognized goal for the treatment of diabetes.

Multiple third-party clinical trials have demonstrated clinical outcome benefits from maintaining control of a patient's glycemic parameters. However, achieving and maintaining control of plasma glucose levels can be difficult in Type 2 diabetes. Numerous drug therapies exist for the treatment of diabetes, such as insulin, metformin, sulfonylureas, thiazolidinediones, or TZDs, and GLP 1 agonists. Unfortunately, many of these approved therapies are sub-optimal from an efficacy, cost, or risk-benefit perspective.